Efficacy and safety of intralesional triamcinolone acetonide in the treatment of chronic hand eczema

This randomized controlled clinical trial was conducted to assess the efficacy and safety of intralesional triamcinolone acetonide in the treatment of chronic hand eczema comparing with topical clobetasol propionate. A total 60 patients of chronic hand eczema were recruited in the study. Thirty patients (Group A) were treated with intralesional triamcinolone acetonide and the rest 30 (Group B) with topical clobetasol propionate. Severity and improvement were assessed using Hand Eczema Severity Index (HECSI) score. The patients of both groups were followed up at 4th week and 12th week. In Group A, median HECSI score at baseline, 4th week and 12th week were 3, 20 and 20 respectively; whereas these scores were 54, 10 and 8 in Group B. In both groups, HECSI score was decreased gradually but the rate was higher in Group B than Group A (p<0.05). Thinning of skin, an adverse effect, was seen in patients of both the intralesional triamcinolone acetonide (10%) and topical clobetasol propionate (16.7%) groups (p>0.05). The result of this study demonstrates that intralesional triamcinolone acetonide is effective and safe in treating chronic hand eczema but less effective than the topical clobetasol.

Download Full-text

Impact of the 25-Hydroxycholecalciferol Concentration and Vitamin D Deficiency Treatment on Changes in the Bone Level at the Implant Site during the Process of Osseointegration: A Prospective, Randomized, Controlled Clinical Trial

Journal of Clinical Medicine ◽

10.3390/jcm10030526 ◽

2021 ◽

Vol 10 (3) ◽

pp. 526

Author(s):

Jakub Kwiatek ◽

Aleksandra Jaroń ◽

Grzegorz Trybek

Keyword(s):

Vitamin D ◽

Vitamin D Deficiency ◽

Controlled Clinical Trial ◽

Randomized Controlled ◽

Group A ◽

Bone Level ◽

Group B ◽

Implant Treatment ◽

Correct Level ◽

25 Hydroxycholecalciferol

Introduction: The most important factor which is responsible for the positive course of implant treatment is the process of osseointegration between the implant structure and the host’s bone tissue. The aim of this study was to assess what effect the 25-hydroxycholecalciferol concentration and vitamin D deficiency treatment have on changes in the bone level at the implant site during the process of osseointegration in the mandible. Materials and Methods: The study was with 122 people qualified for implant surgery, who were assigned to three research groups (A, B, and C). Laboratory, clinical, and radiological tests were performed on the day of surgery, and after 6 and 12 weeks. The bone level in the immediate proximity of the implant was determined by radiovisiography (RVG). Results: The bone level after 12 weeks in Groups B and C was significantly higher than after 6 weeks. The bone level in the study Group B was significantly higher than in Group A. The study showed that the higher the levels of 25-hydroxycholecalciferol were observed on the day of surgery, the higher was the level of bone surrounding the implant after 6 and 12 after surgery. Conclusion: The correct level of 25-hydroxycholecalciferol on the day of surgery and vitamin D deficiency treatment significantly increase the bone level at the implant site in the process of radiologically assessed osseointegration.

Download Full-text

A comparative study of the efficacy and safety of oral apremilast versus oral methotrexate in patients with moderate to severe chronic plaque psoriasis

International Journal of Research in Dermatology ◽

10.18203/issn.2455-4529.intjresdermatol20184462 ◽

2018 ◽

Vol 4 (4) ◽

pp. 563

Author(s):

Vinma H. Shetty ◽

Saumya Goel ◽

Amita Murali Babu ◽

Hafsa Eram

Keyword(s):

Comparative Study ◽

Plaque Psoriasis ◽

Systemic Disease ◽

Severity Index ◽

Pde4 Inhibitor ◽

Efficacy And Safety ◽

Chronic Plaque Psoriasis ◽

Oral Methotrexate ◽

Group A ◽

Group B

Background: Psoriasis is a chronic, inflammatory systemic disease. Methotrexate acts by inhibiting dihydrofolic reductase enzyme. Apremilast is an oral PDE4 inhibitor approved by US Food and Drug Administration for treatment of psoriasis.Methods: This is hospital based comparative study conducted from February 2018 to August 2018. Seventy patients above 18 years of age with chronic plaque psoriasis were divided into 35 patients in each group and were treated with oral Apremilast (30 mg twice daily) and oral methotrexate (15 mg per week in three divided doses with a 12-hour interval between doses and tab folic acid on methotrexate free days) and were evaluated every 4 weeks for a period of 16 weeks and followed-up at 24th week. Outcome was assessed on basis of psoriasis area-and-severity index score (PASI), psoriasis disability index (PDI) and clinical photographs.Results: % of improvement in Group-A patients (76.8%) after 16 weeks of treatment was relatively more (p<0.05) as compared to group B (71.5%). At the end of 16 weeks PASI score in methotrexate group was statistically significant (p<0.05) as compared to group B, PDI became 17.90±3.87 in group A and was statistically significant (p<0.05) as compared to group B which was 20.34±2.98. Side effects observed were comparatively less in group A patients.Conclusions: On comparing the two drugs, methotrexate was comparatively better tolerated and had better efficacy and safety. More studies are required to further prove the efficacy of Apremilast in treatment of psoriasis.

Download Full-text

Randomized Controlled Clinical Trial Comparing Transurethral Eneucleation and Resection of Prostate and Trans-urethral Resection of Prostate in the Management of Benign Prostatic Hyperplasia

BIRDEM Medical Journal ◽

10.3329/birdem.v7i3.33783 ◽

2017 ◽

Vol 7 (3) ◽

pp. 216-220

Author(s):

Md Mehedi Hasan ◽

Samira Rahat Afroze ◽

Muhammad Abdur Rahim ◽

Muhammad Abdus Salam

Keyword(s):

Controlled Trial ◽

Ethical Review ◽

Control Group ◽

Controlled Clinical Trial ◽

Transurethral Resection Of Prostate ◽

Randomized Controlled ◽

Significant Difference ◽

Group A ◽

The Mean ◽

Group B

Background: Transurethral resection of prostate (TURP) is the predominant surgical procedure for benign prostatic hypertension (BPH) but is not devoid of complications like capsular perforation, drop in Hb%, drop in Na+, residual adenoma; hence endeavors are evolving to combat such complications. A newer technique transurethral enucleation and resection of prostate (TUERP) has been devised to solve these problems. This study was designed to compare the safety and the efficacy of newer technique, TUERP with widely practiced TURP Methods: This randomized controlled trial was done at BSMMU, after getting ethical approval from the ethical review committee of the institute, from January to October, 2009. A total of 60 BPH patients were purposively enrolled in this study, after obtaining informed written consent and they were randomized as control, Group A (30 patients, underwent TURP) and experimental group, Group B (30 patients, underwent TEURP).Results: The mean preoperative Hb% level of Group A was 15.1 gm% (SD ± 0.5) and perioperative Hb% level was 13.04 gm% (SD ± 6.06). There was significant difference (P <0.05). The mean preoperative Hb% of Group B was 15.2 gm% (SD ± 0.5) and perioperative Hb% was 15.2 gm% (SD ± 0.48). There was no difference (P >0.05). The mean preoperative Na + of Group A was 140 mmol/l (SD ± 4.1) and perioperative Na+ was 126 mmol/l (SD ± 6.8). There was significant difference (P<0.01). The mean preoperative Na+ of Group B was 136 mmol/l (SD ± 4) and perioperative Na+ was 136 mmol/l (SD ± 2.70). There was no difference (P >0.05).Conclusion: TUERP eliminates drop in Hb% and Na+which are usual consequences following TURP. Thus TUERP can be advocated in the treatment of BPH as it also allows completeresection down to surgical capsule.Birdem Med J 2017; 7(3): 216-220

Download Full-text

A Double-Blind, Randomized Controlled 12-Week Follow-Up Trial to Evaluate the Efficacy and Safety of Polycan in Combination with Glucosamine for the Treatment of Knee Osteoarthritis

Evidence-based Complementary and Alternative Medicine ◽

10.1155/2019/9750531 ◽

2019 ◽

Vol 2019 ◽

pp. 1-8 ◽

Cited By ~ 1

Author(s):

Thi Thanh Thuy Truong ◽

Jong Min Lim ◽

Hyung-Rae Cho ◽

Young Suk Kim ◽

Duc Giang Dao ◽

...

Keyword(s):

Knee Osteoarthritis ◽

Rescue Medication ◽

Secondary Outcome ◽

Control Group ◽

Efficacy And Safety ◽

Double Blind ◽

Randomized Controlled ◽

Patient Reported ◽

Group A ◽

Group B

Aim. The aim of the present study was to examine the efficacy and safety of Polycan, a β-glucan produced from the black yeast Aureobasidium pullulans SM-2001, in combination with glucosamine in reducing knee osteoarthritis-associated symptoms. Methods. This was a double-blind, randomized controlled trial of a formulated product composed of 16.7 mg of Polycan and 250 mg of glucosamine (Group A), 16.7 mg of Polycan and 500 mg of glucosamine (Group B), or 500 mg of glucosamine (control group) per capsule, administered as three capsules once per day over a period of 12 weeks, conducted with 100 osteoarthritis patients, aged 35–80 years. The primary outcome measure was osteoarthritis symptoms assessed by the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) questionnaire. The secondary outcome measures included rescue medication use (according to data from a patient-reported diary) and other safety indices (body weight, blood pressure, hematological, and biochemistry markers). Results. Compared with the control group, Group B demonstrated a statistically significant reduction in the total WOMAC score after 12 weeks of treatment (p < 0.05). There was a significant reduction in the frequency of rescue medication used in Groups A and B compared with the control group (p < 0.05). There were no significant changes in hematology and biochemistry parameters or health indices between the active and the control group. Conclusion. Among patients with mild or moderate osteoarthritis, a daily oral dose of Polycan (50 mg) in combination with glucosamine (750 mg or 1500 mg; Group A or B, respectively) resulted in a better treatment outcome than treatment with glucosamine (1500 mg) alone.

Download Full-text

Efficacy and safety of the combination nifuratel-nystatin and clindamycin-clotrimazole, in the treatment of bacterial vaginosis. Randomized controlled clinical trial

10.36811/ijrmsh.2021.110010 ◽

2021 ◽

pp. 1-10

Author(s):

Franklin José Espitia De La Hoz

Keyword(s):

Clinical Trial ◽

Bacterial Vaginosis ◽

Reproductive Age ◽

Controlled Clinical Trial ◽

Efficacy And Safety ◽

Randomized Controlled Clinical Trial ◽

Cure Rate ◽

Clinical Criteria ◽

Randomized Controlled ◽

Group B

Introduction: Bacterial vaginosis (BV) is the most frequent gynecological infection in women of reproductive age, thus driving the search for effective and safe treatments. Objective: To compare the efficacy and safety of the combination nifuratel-nystatin and clindamycinclotrimazole, in the treatment of bacterial vaginosis. Materials and Methods: Randomized controlled clinical trial in 147 single women (18 to 39 years old), non-pregnant and sexually active, with a diagnosis of BV according to the Amsel clinical criteria and the Nugent score; between 2016 and 2018. In a highly complex private clinic in Armenia, Colombia. Women were randomized into two groups: "A" (73 participants: nifuratel (500 mg) - nystatin (100,000 IU) and "B" (74 participants: clindamycin (100 mg) - clotrimazole (200 mg)); both groups were treated with vaginal ovules, "A" for six days and "B" for three days. All participants were followed-up for clinical and microbiological healing at 7 and 30 days, respectively, after completion of treatment, the STATA® 14.0 program was used. Results: The mean age of women was 28.35±5.79 years. The clinical cure rate with the nifuratelnystatin combination was 93.15%, and that of clindamycin-clotrimazole 97.29%, (p=0.123). The microbiological cure rate with the nifuratel-nystatin combination was 87.67%, and that of clindamycin-clotrimazole 93.24%, (p=0.102). Regarding safety, there were also no significant differences between the two groups (p=0.144); Mild adverse reactions were observed. Recurrence in group "A" was 12.32% compared to 6.75% in group "B" (p>0.05). Conclusions: In this study, the combinations nifuratel (500 mg) -nystatin (100,000 IU) and clindamycin (100 mg)-clotrimazole (200 mg), reported that both are equally effective and safe options in the treatment of BV. It is necessary to evaluate the effect and safety of other combinations in order to implement timely interventions. Keywords: Vaginosis; Bacterial; Efficacy; Safety; Nifuratel; Nystatin; Clindamycin; Clotrimazole.

Download Full-text

Increase of PlGF (Placental Growth Factor) Level After Administration of Dydrogesterone in Pregnancy

KnE Medicine ◽

10.18502/kme.v1i1.530 ◽

2016 ◽

Vol 1 (1) ◽

Cited By ~ 1

Author(s):

Dewi Karlina Rusly

Keyword(s):

Folic Acid ◽

Controlled Clinical Trial ◽

Randomized Controlled ◽

Significant Difference ◽

Before And After ◽

Group A ◽

Study Population ◽

The Mean ◽

Group B ◽

In Pregnancy

Aim: To observe the effect of Dydrogesterone administration in pregnancy on PlGF levelMethods: This is a randomized controlled clinical trial. Study population has been divided into two groups. Group A consists of 20 women who receive only Folic acid 5 mg a day for 4 weeks time. Group B consists of 20 women who receive Dydrogesterone 2x10 mg a day and Folic acid 5 mg a day for 4 weeks. PlGF has been measured twice. First measurement was done before drug administration, while the second measurement has been done during 18th weeks of pregnancy. The changes on PlGF level before and after treatment from each group has been analyzed using SPSS 17.Results: 40 pregnant women have been recruited for this study. There are no differences based on the patient’s age, number of pregnancy and parity, gestational age and body weight between each group. The mean levels of PlGF in both groups before intervention shows no significant difference (p = 0091 or p> 0.05), 40.80 pg/mL vs. 25.95 pg / mL. The mean levels of PlGF in group A after 4 weeks administration of Folic acid is 89.60 pg / mL. It shows the escalation of 48.8 pg / mL. The elevation of PlGF level in group A shows significant difference (p = 0.000 or p <0.05) after 4 weeks Folic acid treatment.The mean levels of PlGF in group B after 4 weeks administration of Dydrogesterone and Folic acid is 212.15 pg / mL. It shows the escalation of 186.20 pg / mL. The elevation of PlGF level in group B shows significant difference (p = 0.000 or p <0.05) after 4 weeks Dydrogesterone and Folic acid treatment.Conclusion: Dydrogesterone treatment can increase the level of PlGF.

Download Full-text

Risk-Stratification Directed Prophylaxis with Additional Low-Dose of Methylprednisolone Can Reduce Acute Graft-Versus-Host Disease for Patients with Hematological Malignancies after Allogeneic SCT: A Randomized, Controlled, Clinical Trial

Blood ◽

10.1182/blood.v124.21.40.40 ◽

2014 ◽

Vol 124 (21) ◽

pp. 40-40

Author(s):

Ying-Jun Chang ◽

Yu Wang ◽

Lan-Ping Xu ◽

Dai-Hong Liu ◽

Kai-Yan Liu ◽

...

Keyword(s):

High Risk ◽

Risk Stratification ◽

Low Dose ◽

Acute Gvhd ◽

Controlled Clinical Trial ◽

Graft Versus Host ◽

Randomized Controlled ◽

Group A ◽

Grade Ii ◽

Group B

Abstract The major complication of allogeneic HSCT-graft-versus-host disease (GVHD)-remains lethal and limits use of this important procedure, especially after unmanipulated haploidentical HSCT. Several studies have provided evidence that universal addition of corticosteroids for prophylaxis of GVHD can reduce the risk for acute GvHD grade II-IV in HLA-matched transplantation. However, corticosteroid, a non-specific immunosuppressive agent, may also contribute to high rates of infections. Our previous data suggest that the ratio of CD4/CD8 in allografts from haploidentical donors can stratify patients into high-risk and low-risk ones who will develop GVHD after transplantation. Recently, we indicated that low-dose of methylprednisolone (MP, 0.5 mg/kg/day) might be a well-tolerated, effective and inexpensive regimen in combination of MTX for therapy of GVHD, suggesting that low-dose corticosteroid may be used for the prophylaxis of GVHD without increasing infection. To investigate whether risk-stratification directed prophylaxis strategy can reduce the incidence of GVHD and improve survival in a hemogenous patient population who underwent unmanipulated haploidentical HSCT, we performed a prospective, randomized, controlled, clinical trial. A total of 228 patients were enrolled in this trial. All of the patients completed the study and were stratified as high-risk (n=145) and low-risk arms (n=83) according to the ratio of CD4/CD8 in allografts. Patients of the high-risk arms were randomly assigned in a 1:1 ratio to additional low-dose glucocorticoid prophylaxis group (Group A, n=72) and control group (GroupB, n=73). The groups were balanced with respect to patient and donor characteristics. Our results showed that the cumulative incidence of grade II-IV acute GVHD on day 100 was 20.9%±4.8% in Group A, which was comparable to Group C (25.5%±4.8%, P=0.430) and both of which were significantly lower than that of Group B (48.1%±5.9%, P＜0.001). In addition, the onset time of grade II-IV acute GVHD was 25 (16-50) days, 15 (9-57) days, and 21 (10-58) days, respectively in Group A, Group B, and Group C (P＜0.05, Group A vs. Group B or Group C). There were no significant difference in grade Ⅲ-IV acute GVHD among these three groups. The ratio of patients who developed glucocorticoid refactory acute GVHD and treated with basiliximab (anti-CD25 antibody) were 13.9% (10/72), 17.8% (13/73), and 22.9% (19/83), respectively, in Group A, Group B, and Group C, there is a trend that the incidence of basiliximab treated patients in Group C is higher than that of Group A (P=0.109). The median time for myeloid engraftment in Group A was 11 days (range: 10-21 days), which was significantly faster that those of Group B (13 days, range from 10 to 33 days, P＜0.05) and Group C (13 days, range from 10 to 33 days, P＜0.05). The median time for platelet engraftment in Group A was 12 days (range: 10-22 days), which was significantly faster that those of Group B (17 days, range from 6 to 255 days, P＜0.01) and Group C (19 days, range from 8 to 260 days, P＜0.01). In addition, risk-stratification directed prophylaxis with additional low-dose of MP did not increase the incidence of CMV, EBV reactivation, PTLD, relapse and TRM, as well as delay immune recovery after unmanipulated haploidentical HSCT. The 100 day cumulative incidence relapse and transplant-related mortality was not significantly different among patients in Group A, Group B, and Group C, respectively. The 100 day probabilities of LFS and OS were comparable among these three patient groups. In conclusion, we for the first time demonstrated that risk-stratification directed prophylaxis for GVHD with additional low-dose of MP could significantly decrease the incidence and delay the onset of grade II-IV acute GVHD without increasing infections and delaying immune recovery. Our data indicated that addition of glucocorticoid early after unmanipulated haploidentical transplantation could also accelerate hematopietic recovery [This study was registered at http://clinicaltrials.gov/ NCT01607580]. Disclosures No relevant conflicts of interest to declare.

Download Full-text

Does low-frequency vibration have an effect on aligner treatment? A single-centre, randomized controlled trial

European Journal of Orthodontics ◽

10.1093/ejo/cjy076 ◽

2018 ◽

Vol 41 (4) ◽

pp. 434-443

Author(s):

Luca Lombardo ◽

Angela Arreghini ◽

Luis T Huanca Ghislanzoni ◽

Giuseppe Siciliani

Keyword(s):

Orthodontic Treatment ◽

Tooth Movement ◽

Controlled Trial ◽

Low Frequency ◽

Controlled Clinical Trial ◽

Single Centre ◽

Randomized Controlled ◽

Low Frequency Vibration ◽

Group A ◽

Group B

Summary Background Low-frequency vibrations have been proposed as a means of accelerating tooth movement and reducing orthodontic treatment times. Objective To determine any differences in the accuracy of dental movement in patients treated with a low-frequency vibration aligner protocol and/or by reducing the aligner replacement interval with respect to a conventional protocol. Design This trial was designed as a single-centre, randomized controlled clinical trial. Methods Participants: Patients (aged 27.1 ± 9.0 years) who required orthodontic treatment with aligners. Randomization: Patients were randomly allocated to three arms as determined by a computer-randomization scheme. Group A were assigned a conventional protocol (aligners replaced every 14 days); group B also used a low-frequency vibration device for 20 minutes per day; group C followed the same vibration protocol but replaced their aligners every 7 days. Blinding: The operator who performed the set-up and the one who analysed the data were blinded to the group of the patients. Outcome: Pre- and post-treatment digital models were analysed using VAM software to identify the accuracy/imprecision of dental movements. One-way analysis of variance (P < 0.05) and the Bonferroni post hoc test were used to identify any statistically significant differences between the three arms in terms of the accuracy of tooth movement versus the prescription. Results Numbers analysed: A total of 45 patients (15 for group) were analysed (i.e. 2286 dental movements). Outcome: No statistically significant differences emerged between groups A and C in the upper arch, or among groups A, B, and C in the lower. Group B displayed significantly greater accuracy with respect to group A in upper incisor rotation (P = 0.016), and to group C in vestibulolingual (P = 0.007) and mesiodistal tipping (P = 0.029) of the upper canines, and vestibulolingual tipping of the upper molars (P = 0.0001). Harms: No adverse events or side-effects were registered. Conclusions Considering all tooth and movement types of the 45 participants, the mean total imprecision was 2.1 ± 0.9 degrees, with respect to a mean prescription of 5.7 ± 2.2 degrees. There was no difference in accuracy between replacing the aligners accompanied by low-frequency vibration every 7 days and replacing them every 14 days without vibration. Moreover, low-frequency vibration seemed to improve the accuracy of a conventional protocol in terms of upper incisor rotation. Trial registration The German Clinical Trials Register (DRK00015613).

Download Full-text

A COMPARATIVE CLINICAL STUDY OF KADALI KSHAR PRATISARAN AND INJ. SETROL IN THE MANAGEMENT OF ABHYANTAR ARSHA W.S.R. TO INTERNAL HAEMORRHOIDS.

10.36106/ijsr/7601868 ◽

2019 ◽

pp. 1-3

Author(s):

Amit Paliwal

Keyword(s):

Clinical Study ◽

Control Group ◽

Controlled Clinical Trial ◽

Randomized Controlled ◽

Detailed Explanation ◽

Comparative Clinical Study ◽

Group A ◽

Group B ◽

And Control

There is a very peculiar role of “Kshar Karma” (an Anushastra), in the management of Arsha, as described by Sushrutacharya.Acharyas have mentioned Kadali as suitable for the Kshara formulation. Patients suffering from AbhyantaraArsha are subjected to KadaliPratisaraneeyaKshar and efficacy ofKadaliKsharPratisaran and inj. Setrol is compared in the management of AbhyantarArsha. In Clinical study an Open randomized controlled clinical trial is conducted of trial group A and control group B for 30 patients in each group.In observations a detailed explanation is given aboutdistribution of patients according to age, sex, occupation.The results of the study are analyzed statistically compared and are presented in tables and graphs form. By highlighting the outcome of the study along with limitations and scope of further improvement it is concluded that KadaliKsharpratisarana gives potent effects in AbhyantarArsha

Download Full-text

Determination of Ballistic Six Exercises and Theraband Exercises on Physical Performance in Badminton Players: A Randomized Controlled Clinical Trial

Journal of Pharmaceutical Research International ◽

10.9734/jpri/2021/v33i49a33331 ◽

2021 ◽

pp. 281-291

Author(s):

Simran Narang ◽

Deepali Patil

Keyword(s):

Controlled Trial ◽

Exercise Group ◽

Controlled Clinical Trial ◽

Kinetic Chain ◽

Randomized Controlled ◽

Shoulder Strength ◽

Group A ◽

Group B ◽

And Function ◽

Medicine Ball

Aims: During regular training, players sustain injuries on a regular basis. Based on the fact that badminton isn't seem at all a contact sport the majority of ailments are caused by overuse. A participant must perform a variety of quick yet repeated shoulder actions and repetitive motions put tension mostly on tissues with time, putting them at risk of damage. Current study was done to compare the effects of Ballistic Six training and Theraband exercises on shoulder strength, agility, speed and function in novice badminton player. Study Design: Randomized Controlled Trial. Place and Duration of Study: Sport clubs were selected according to feasibility in Wardha, from July 2020 to June 2021. Methodology: 40 subjects of both gender aged between 18 to 25 years were selected who have being playing badminton for more than a year. Subjects were randomized into two groups, Group A (Ballistic Six Exercise group) and Group B (Theraband exercise group). Assessments done were sitting medicine ball throw test (SMBT) for shoulder strength, closed kinetic chain upper extremity stability test (CKUCEST) for agility, plate tapping test (PTT) for speed and Kerlan Jobe Orthopaedic Clinical Score (KJOC) for shoulder function. Assessments were done at baseline, post 8 weeks of training and at the end of 6 months. Results: Significant increase in mean sitting medicine ball throw test SMBT, CKUCEST, PTT and KJOC score in both group but Group A showed more improvement than Group B. Conclusion: Study concluded that adding of Ballisitic Six plyometric training for novice badminton players would increase the shoulder strength, agility, speed and function than the theraband exercises.

Download Full-text